Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.640
-0.020 (-1.20%)
At close: Sep 12, 2025, 4:00 PM EDT
1.670
+0.030 (1.83%)
After-hours: Sep 12, 2025, 6:58 PM EDT
Immutep Revenue
In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M AUD with 31.28% growth. Immutep had revenue of 1.90M in the half year ending June 30, 2025, with 4.17% growth.
Revenue (ttm)
5.04M AUD
Revenue Growth
+31.28%
P/S Ratio
67.74
Revenue / Employee
162,702 AUD
Employees
31
Market Cap
224.01M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMMP News
- 5 days ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 6 weeks ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 6 weeks ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 3 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 4 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 4 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 5 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire